The report offers insight on developments in emerging specialty therapies. Last year, the FDA Center for Drug Evaluation and Research approved 22 novel new drugs. While there was a reduction in novel new drugs compared to previous years, there were several expanded indications for previously approved therapies that allowed these drugs to reach additional patient populations. New approvals included a mix of oncology, immunology, rare diseases, and other disease states.

Sign up to read our White Paper and receive helpful updates from Diplomat.